Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2023:

• Cash: € 285,764.46
• Number of shares: 129,659
• Number of executions on buy side on semester: 1,886
• Number of executions on sell side on semester: 1,610
• Traded volume on buy side on semester: 322,578 shares for € 1,074,534.26
• Traded volume on sell side on semester: 276,147 shares for € 938,985.90

At the last half-year report as of December 31, 2023, the following resources were available in the liquidity account: 

• Cash: € 416,331.34
• Number of shares: 83,228
• Number of executions on buy side on semester: 828
• Number of executions on sell side on semester: 877
• Traded volume on buy side on semester: 157,508 shares for € 584,045.97
• Traded volume on sell side on semester: 180,395 shares for € 695,421.23

When the contract was initially implemented, the following resources were included in the liquidity account:

• Cash: € 163,510.42
• Number of shares: 34,063

	Buy Side				Sell Side
	Number of executions	Number of shares	Traded volume in EUR		Number of executions	Number of shares	Traded volume in EUR
Total	1 886	322 578	1 074 534,26		1 610	276 147	938 985,90
01/02/2024	15	2 500	10 275,00		19	3 507	14 589,12
01/03/2024	5	1 000	4 140,00		2	1 000	4 190,00
01/04/2024	9	2 500	10 425,00		15	4 793	20 561,97
01/05/2024	11	2 463	9 999,78		-	-	-
01/08/2024	5	1 500	6 165,00		10	3 373	13 997,95
01/09/2024	15	3 522	14 193,66		4	1 240	5 096,40
01/10/2024	12	2 978	11 971,56		5	1 024	4 126,72
01/11/2024	21	6 499	25 021,15		-	-	-
01/12/2024	3	1 500	5 625,00		8	2 000	7 720,00
01/15/2024	15	3 500	12 705,00		2	282	1 026,48
01/16/2024	14	2 000	7 160,00		2	501	1 803,60
01/17/2024	23	3 427	11 891,69		2	192	683,52
01/18/2024	13	3 073	10 386,74		13	3 000	10 230,00
01/19/2024	2	500	1 700,00		6	1 250	4 275,00
01/22/2024	13	3 000	10 230,00		8	1 500	5 235,00
01/23/2024	3	1 500	5 115,00		16	4 716	16 694,64
01/24/2024	6	2 000	7 040,00		9	1 100	3 894,00
01/25/2024	8	1 500	5 265,00		1	1	3,56
01/26/2024	8	1 600	5 616,00		4	1 499	5 321,45
01/29/2024	10	1 000	3 530,00		7	2 054	7 291,70
01/30/2024	9	2 500	8 825,00		9	1 836	6 536,16
01/31/2024	12	2 751	9 600,99		10	1 302	4 570,02
02/01/2024	13	4 000	13 840,00		4	1 000	3 500,00
02/02/2024	13	3 001	10 293,43		5	1 030	3 574,10
02/05/2024	13	3 096	10 619,28		12	4 971	17 199,66
02/06/2024	19	2 904	9 931,68		7	2 000	6 900,00
02/07/2024	25	6 000	19 980,00		1	50	173,00
02/08/2024	8	1 500	4 875,00		10	1 314	4 296,78
02/09/2024	11	2 000	6 380,00		11	1 500	4 845,00
02/12/2024	13	1 750	5 810,00		31	8 636	29 103,32
02/13/2024	17	3 587	12 303,41		15	2 750	9 542,50
02/14/2024	12	2 250	7 807,50		18	3 629	12 737,79
02/15/2024	10	2 000	7 000,00		26	4 939	17 533,45
02/16/2024	44	10 663	31 882,37		13	2 500	7 625,00
02/19/2024	19	2 137	6 624,70		29	4 750	14 962,50
02/20/2024	25	3 613	11 091,91		7	1 001	3 123,12
02/21/2024	9	1 760	5 332,80		3	351	1 084,59
02/22/2024	13	1 721	5 231,84		2	251	773,08
02/23/2024	24	3 770	11 196,90		1	250	750,00
02/26/2024	15	2 250	6 592,50		12	2 250	6 660,00
02/27/2024	13	2 250	6 772,50		38	5 167	16 017,70
02/28/2024	14	2 010	6 130,50		21	3 732		11 755,80
02/29/2024	15	2 000	6 320,00		8	1 250		3 987,50
03/01/2024	12	2 029	6 492,80		20	3 500		11 410,00
03/04/2024	15	2 501	8 228,29		21	4 251		14 283,36
03/05/2024	23	3 500	11 725,00		28	2 308		7 916,44
03/06/2024	28	3 749	12 221,74		9	1 458		4 796,82
03/07/2024	14	1 573	5 112,25		12	2 500		8 250,00
03/08/2024	21	3 997	13 190,10		25	4 601		15 505,37
03/11/2024	16	2 250	7 560,00		20	2 999		10 196,60
03/12/2024	13	1 956	6 787,32		28	3 900		13 728,00
03/13/2024	10	1 530	5 355,00		24	2 500		8 875,00
03/14/2024	22	4 250	15 172,50		31	6 000		21 840,00
03/15/2024	16	2 000	7 320,00		39	4 750		17 622,50
03/18/2024	18	2 000	7 560,00		37	5 500		21 010,00
03/19/2024	101	20 564	75 881,16		34	6 863		28 550,08
03/20/2024	31	5 750	18 802,50		11	1 770		5 876,40
03/21/2024	2	500	1 635,00		43	5 730		19 596,60
03/22/2024	21	2 781	9 511,02		8	1 250		4 325,00
03/25/2024	12	1 750	6 055,00		14	1 750		6 142,50
03/26/2024	16	2 469	8 320,53		16	3 250		11 310,00
03/27/2024	32	5 000	17 050,00		5	1 250		4 400,00
03/28/2024	29	5 625	18 056,25		24	4 251		13 943,28
04/02/2024	14	2 750	9 047,50		11	1 829		6 108,86
04/03/2024	5	500	1 675,00		9	1 420		4 771,20
04/04/2024	12	2 000	6 680,00		8	1 500		5 085,00
04/05/2024	-	-	-		8	500		1 685,00
04/08/2024	7	1 250	4 162,50		23	3 280		11 152,00
04/09/2024	9	1 210	4 198,70		20	3 720		13 131,60
04/10/2024	13	2 790	9 792,90		6	275		981,75
04/11/2024	29	4 001	13 683,42		2	24		82,56
04/12/2024	16	2 551	8 571,36		12	1 193		4 068,13
04/15/2024	42	4 949	16 282,21		21	4 503		15 040,02
04/16/2024	45	6 865	21 830,70		-	-		-
04/17/2024	8	603	1 893,42		11	1 686		5 361,48
04/18/2024	10	1 997	6 370,43		8	1 264		4 070,08
04/19/2024	10	1 079	3 388,06		6	1 000		3 190,00
04/22/2024	8	1 000	3 170,00		5	500		1 600,00
04/23/2024	9	1 051	3 289,63		-	-		-
04/24/2024	12	1 730	5 311,10		1	250		775,00
04/25/2024	4	740	2 227,40		4	444		1 367,52
04/26/2024	4	1 000	2 990,00		2	250		765,00
04/29/2024	15	2 001	5 902,95		19	1 319		3 930,62
04/30/2024	16	1 851	5 478,96		2	208		624,00
05/02/2024	4	524	1 566,76		17	2 993		9 008,93
05/03/2024	-	-	-		46	7 114		22 053,40
05/06/2024	4	751	2 440,75		42	6 513		21 362,64
05/07/2024	8	1 503	4 989,96		20	3 250		10 920,00
05/08/2024	17	2 497	8 115,25		5	750		2 452,50
05/09/2024	9	1 749	5 649,27		3	175		570,50
05/10/2024	3	260	837,20		8	1 525		4 956,25
05/13/2024	19	2 763	9 421,83		56	9 234		31 764,96
05/14/2024	10	2 250	7 695,00		14	2 250		7 762,50
05/15/2024	8	1 000	3 470,00		18	3 054		10 689,00
05/16/2024	24	3 595	12 438,70		9	1 446		5 089,92
05/17/2024	14	1 850	6 586,00		38	5 835		21 006,00
05/20/2024	9	732	2 627,88		4	864		3 119,04
05/21/2024	8	1 279	4 578,82		8	1 250		4 487,50
05/22/2024	69	13 641	45 833,76		-	-		-
05/23/2024	10	1 000	3 340,00		14	2 750		9 267,50
05/24/2024	12	1 921	6 339,30		9	1 500		5 010,00
05/27/2024	16	4 319	13 691,23		18	3 000		9 630,00
05/28/2024	12	1 289	4 111,91		5	1 001		3 203,20
05/29/2024	11	923	2 944,37		26	2 046		6 547,20
05/30/2024	2	427	1 357,86		8	1 250		4 050,00
05/31/2024	-	-	-		18	3 750		12 637,50
06/03/2024	4	500	1 645,00		-	-		-
06/04/2024	1	250	815,00		6	500		1 655,00
06/05/2024	12	751	2 463,28		2	2		6,60
06/06/2024	6	579	1 870,17		4	249		816,72
06/07/2024	5	671	2 147,20		-	-		-
06/10/2024	18	1 560	5 023,20		23	4 413		14 342,25
06/11/2024	24	3 511	11 129,87		5	1 250		4 012,50
06/12/2024	50	7 534	22 526,66		3	486		1 535,76
06/13/2024	30	3 450	10 315,50		23	3 850		11 858,00
06/14/2024	39	5 700	16 131,00		1	250		750,00
06/17/2024	26	5 750	14 835,00		26	4 265		11 259,60
06/18/2024	16	2 680	6 834,00		12	1 600		4 128,00
06/19/2024	-	-	-		20	5 432		14 938,00
06/20/2024	9	1 750	4 690,00		4	750		2 115,00
06/21/2024	-	-	-		3	500		1 375,00
06/24/2024	-	-	-		12	2 150		6 127,50
06/25/2024	22	3 545	10 138,70		7	912		2 663,04
06/26/2024	16	2 057	5 800,74		7	939		2 657,37
06/27/2024	4	500	1 415,00		11	1 761		5 071,68
06/28/2024	18	2 750	7 837,50		2	251		725,39

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva Pascaline Clerc, PhD EVP, Strategy and Corporate Affairs    [e-mail]    [phone]

Brunswick Group Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau Media relations [e-mail]    [phone]

Westwicke, an ICR Company Patricia L. Bank Investor relations [e-mail]          [phone]

Achats

 

Ventes

Attachment

• Inventiva - PR - Liquidity Contract - S1 24 - EN - 19 07 2024